Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MPI | P34949 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3090713 | 0.84 | POLB (0.77) | MAPTNPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL3092053 | 0.83 | MAPT (0.71) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL30794484 | 0.83 | MAPT (0.71) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL15224256 | 0.82 | KMT2A (0.83) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL15224268 | 0.81 | KMT2A (0.76) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL15224269 | 0.79 | KMT2A (0.86) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL11792815 | 0.78 | HTT (0.73) | MAPTNPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL3070168 | 0.77 | HTR1A (0.69) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL2824053 | 0.77 | KMT2A (1.00) | MAPTNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL14224489 | 0.76 | KMT2A (0.73) | MAPTNPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | claimed |
| EP-2164837-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-03-24 | — | — | EP | claimed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | claimed |
| US-20100227870-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-09 | — | — | US | disclosed |
| EP-2164837-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008152089-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227870-A1 | Novel Compounds | GRM5, GRIK5, GRM1 | MAPT 1435/4885NPC1 1352/4885RAB9A 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.